Journal
CLINICAL INFECTIOUS DISEASES
Volume 64, Issue 5, Pages 666-674Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciw811
Keywords
acute kidney injury; nephrotoxicity; vancomycin; piperacillin-tazobactam
Categories
Funding
- Cubist Pharmaceuticals of Merck
- Allergan, PLC
Ask authors/readers for more resources
Concomitant vancomycin and piperacillin/tazobactam (PT) may be associated with increased acute kidney injury (AKI) compared to vancomycin without PT. Medline, Cochrane, and Scopus were searched through October 2016 using vancomycin, piperacillin, tazobactam, and AKI, acute renal failure, or nephrotoxicity. A registered meta-analysis (PROSPERO: CRD42016041646) with relevant scenarios was performed. Fourteen observational studies totaling 3549 patients were analyzed. Concomitant vancomycin and PT was associated with AKI in unadjusted odds ratio (OR, 3.12; 95% confidence interval [CI], 2.04-4.78) and in adjusted OR (aOR, 3.11; 95% CI, 1.77-5.47) analyses. Similar findings were seen assessing studies in adults (aOR, 3.15; 95% CI, 1.72-5.76), children (OR, 4.55; 95% CI, 2.71-10.21), and when <50% of patients received care in an intensive care unit (aOR, 3.04; 95% CI, 1.49-6.22) but not >= 50% (aOR, 2.83; 95% CI, 0.74-10.85). Increased AKI with concomitant vancomycin and PT should be considered when determining beta-lactam therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available